Chinese biotech company LTZ Therapeutics has announced the completion of its series A financing round, raising over $20 million.
The firm, which has a strong presence in California, will use the money to advance the development of its Myeloid Engager pipeline to treat cancer and autoimmune diseases.
The round was led by new investor Lapam Capital, with participation from GL Ventures, K2 Venture Partners, and Shunwei Capital.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze